Lipigon signs multi-million gene therapy deal
Life science company Lipigon Pharmaceuticals has signed an agreement for its gene therapy project with listed company CombiGene. “If everything goes well this agreement could potentially be worth millions. But it also enables us to develop our business in the short term, not least because we can now employ highly competent staff in Umeå,” says Stefan K Nilsson, CEO of Lipigon.